1996•PubMedRequires access
[The immunogenicity of the Heberbiovac-HB vaccine in children].
Manuel Díaz González, A Chiang Macía, D Díaz Acosta, José Ramón González, L Rodríguez Lay, Plácido Pedroso Flaquet, Amelia Urbino López-Chávez
Open publisher page 5 citations
Abstract
The Cuban recombinant vaccine against hepatitis B virus was applied with doses of 10 ìg to children under 15 in a scheme from 0, 1 to 6 months. The immunogenicity was evaluated at 2, 7, and 12 months and showed 100% of seroconversion with protective titres. 65.9, 100, and 83.5% of the vaccinated attained titres higher that 100 UI/L at 60, 210, and 360 days. The geometrical mean was of 213.6, 8208.2, and 568.0 UI/L, respectively. All the groups obtained 100% of seroconversion; however, there were significant differences (p < 0.05) in favor of the preschool and school children compared with those over 10 as regards the response level (titres higher than 100 UI/L) and the geometrical mean of antibody titres in the 3 samples. It was demonstrated the high immunogenic power of the vaccine at these ages, which makes it recommendable for their protection against the hepatitis B virus (HBV).